Prospective study of endometrial cancer treatment in relation to molecular markers in curettage specimens
- Prosjektnummer
- 911371
- Ansvarlig person
- Jone Trovik
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Forskerutdanning - dr.grad
- Helsekategori
- Cancer
- Forskningsaktivitet
- 6. Treatment Evaluation
High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated.
PLoS One 2012;7(12):e52795. Epub 2012 des 27
PMID: 23300780
Polymorphisms in inflammation pathway genes and endometrial cancer risk.
Cancer Epidemiol Biomarkers Prev 2013 Feb;22(2):216-23. Epub 2012 des 5
PMID: 23221126
KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.
Br J Cancer 2012 Dec;107(12):1997-2004. Epub 2012 okt 25
PMID: 23099803
ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
Mod Pathol 2013 Mar;26(3):428-34. Epub 2012 okt 19
PMID: 23080032
Markers for individualised therapy in endometrial carcinoma.
Lancet Oncol 2012 Aug;13(8):e353-61.
PMID: 22846840
Magnetic resonance imaging performs better than endocervical curettage for preoperative prediction of cervical stromal invasion in endometrial carcinomas.
Gynecol Oncol 2012 Sep;126(3):413-8. Epub 2012 mai 15
PMID: 22609110
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.
PLoS One 2012;7(4):e36263. Epub 2012 apr 30
PMID: 22558411
Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists.
Eur Radiol 2012 Jul;22(7):1601-11. Epub 2012 mar 28
PMID: 22453859
Genome-wide association study identifies a possible susceptibility locus for endometrial cancer.
Cancer Epidemiol Biomarkers Prev 2012 Jun;21(6):980-7. Epub 2012 mar 16
PMID: 22426144
Loss of GPER identifies new targets for therapy among a subgroup of ERa-positive endometrial cancer patients with poor outcome.
Br J Cancer 2012 May;106(10):1682-8. Epub 2012 mar 13
PMID: 22415229
Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective.
Gynecol Oncol 2012 May;125(2):381-7. Epub 2012 feb 1
PMID: 22307064 - Inngår i doktorgradsavhandlingen
Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas.
Histopathology 2012 Feb;60(3):516-9. Epub 2011 des 14
PMID: 22168220
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
Eur J Cancer 2012 Sep;48(13):1988-96. Epub 2011 nov 24
PMID: 22119201
Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification.
Gynecol Oncol 2012 Apr;125(1):103-8. Epub 2011 nov 17
PMID: 22100838
A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis.
Eur J Cancer 2013 Feb;49(3):625-32. Epub 2012 okt 1
PMID: 23036850
Evolution in endometrial cancer: evidence from an immunohistochemical study.
Int J Gynecol Cancer 2011 Feb;21(2):316-22.
PMID: 21734474
Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer.
Clin Cancer Res 2011 Jul;17(14):4825-33. Epub 2011 mai 26
PMID: 21616994 - Inngår i doktorgradsavhandlingen
Genome-wide association study identifies a common variant associated with risk of endometrial cancer.
Nat Genet 2011 May;43(5):451-4. Epub 2011 apr 17
PMID: 21499250
High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer.
Br J Cancer 2011 Mar;104(6):921-6. Epub 2011 feb 22
PMID: 21343929
The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study.
Int J Gynecol Cancer 2011 Feb;21(2):332-6.
PMID: 21270614
Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer.
Clin Cancer Res 2011 May;17(10):3368-77. Epub 2011 jan 17
PMID: 21242118 - Inngår i doktorgradsavhandlingen
Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer.
Histopathology 2010 Oct;57(4):641-6.
PMID: 20955391 - Inngår i doktorgradsavhandlingen
Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting.
Am J Obstet Gynecol 2009 Dec;201(6):603.e1-7. Epub 2009 okt 3
PMID: 19800606
Plasma calprotectin concentrations in women with endometrial carcinoma.
Gynecol Oncol 2009 Sep;114(3):491-5. Epub 2009 jul 3
PMID: 19577278
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.
Proc Natl Acad Sci U S A 2009 Mar;106(12):4834-9. Epub 2009 mar 4
PMID: 19261849
Drug-sensitive FGFR2 mutations in endometrial carcinoma.
Proc Natl Acad Sci U S A 2008 Jun;105(25):8713-7. Epub 2008 jun 13
PMID: 18552176
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastases and poor outcome; Results From MoMaTEC
Submitted to JNCI, inngår i avhandlingen
HORMONE RECEPTOR STATUS IN ENDOMETRIAL CARCINOMA CURETTAGE INDEPENDENTLY PREDICTS LYMPH NODE METASTASIS AND PROGNOSIS IN A MULTI
Abstract, Oral presentation at International Gynaecololgical Cancer Society, Prague, Chez Republic Oktober 2010
STATHMIN OVEREXPRESSION IDENTIFIES HIGH RISK PATIENTS AND LYMPH NODE METASTASIS IN ENDOMETRIAL CANCER
Abstract, Oral presentation at International Gynaecololgical Cancer Society, Prague, Chez Republic Oktober 2010
Gene expression signature characterized by PI3Kinase activation validates to identify aggressive disease and a potential for PI3
Abstract, Oral presentation at International Gynaecololgical Cancer Society, Prague, Chez Republic Oktober 2010
High BMI is significantly associated with positive progesterone receptor status and clinico-pathologic markers for non-aggressiv
Abstract, Poster presentation at International Gynaecololgical Cancer Society, Prague, Chez Republic Oktober 2010
Stathmin is superior to AKT and pAKT staining to detect PI3Kinase activation and aggressive endometrial cancer
Bergen Conference on Cancer Research, Solstrand, Mai2009
Lymphadenectomy contributes to identification of high and low risk endometrial cancer in a prospective multicentre settin
European Society Gynecologic Oncology okt-09
Lymfadenektomi bidrar til identifikasjon av høy- og lavrisiko endometriecancer i en prospektiv multisentersetting
Norsk Gynekologisk Forenings årsmøte, september -09
DNA ploidy is a stronger prognostic marker in primary investigation setting than a routine diagnostic setting for endometrial ca
Poster på Int Gyn Cancer Sosciety Congress 25-28.okt 2008 Bangkok
Endometrial carcinoma; can biomarkers aid in the prediction of aggressive disease?
- Disputert:
- mai 2012
- Hovedveileder:
- Helga Salvesen
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest